SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on April 23, 2007, reporting events occurring between March 24, 2007, and April 20, 2007. The registrant is a Colorado corporation headquartered in Castle Rock, CO. Note: The request metadata referenced "Riot Platforms, Inc." and the date "2007 Apr 20," but the source text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing details unregistered sales of equity securities via warrant exercises:
- Cash Proceeds (Current Period): $5,373,708 received from March 24 to April 20, 2007.
- Shares Issued (Current Period): 4,045,586 shares of common stock.
- Cash Proceeds (Earlier 2007): $3,466,247 received prior to this report (reported Feb 27 and March 23, 2007).
- Shares Issued (Earlier 2007): 2,749,214 shares.
- Cashless Exercise: 525,000 warrants surrendered for a net issuance of 374,085 shares (as of March 22, 2007).
- Commissions: None paid.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, debt, or liquidity ratios.
Material Changes
The primary material change is the significant increase in cash proceeds and share count resulting from the exercise of warrants from 2004 and 2005 offerings. The current period activity ($5.37M) exceeds the earlier 2007 activity ($3.47M) reported in previous filings.
Guidance, Outlook, and Use of Proceeds
Management indicated that the funds raised will be utilized for:
- Working capital.
- New product development.
- General corporate purposes.
The offerings were conducted in reliance on Section 4(2) of the Securities Act of 1933 and Rule 506. No specific forward-looking guidance, risk factors, or contingencies were detailed in this specific report.
Investor Verification Checklist
- Verify the total number of outstanding shares post-exercise to assess dilution impact.
- Confirm the specific allocation of the $5.37M proceeds between working capital and R&D in subsequent financial statements.
- Review the terms of the 2004 and 2005 warrant offerings to understand remaining exercise obligations.
- Check for any subsequent filings regarding the cashless exercise terms and their impact on the capital structure.